Literature DB >> 16332055

Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor.

Yujun Zheng1, Karanam Balasubramanyam, Marek Cebrat, Donald Buck, Fabien Guidez, Arthur Zelent, Rhoda M Alani, Philip A Cole.   

Abstract

This paper describes the first potent and selective p300 histone acetyltransferase (HAT) inhibitor which is effective in live cells. This compound 7 is a coenzyme A analogue conjugated to a cell permeabilizing oligoArg peptide via disulfide linkage. This compound was shown to block cellular histone acetylation and transcription using a p300-sensitive reporter. It should thus be broadly useful for dissecting the role of p300 HAT activity in physiologic and disease states.

Entities:  

Year:  2005        PMID: 16332055     DOI: 10.1021/ja0558544

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  25 in total

1.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.

Authors:  Erin M Bowers; Gai Yan; Chandrani Mukherjee; Andrew Orry; Ling Wang; Marc A Holbert; Nicholas T Crump; Catherine A Hazzalin; Glen Liszczak; Hua Yuan; Cecilia Larocca; S Adrian Saldanha; Ruben Abagyan; Yan Sun; David J Meyers; Ronen Marmorstein; Louis C Mahadevan; Rhoda M Alani; Philip A Cole
Journal:  Chem Biol       Date:  2010-05-28

2.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

Review 3.  Chemical probes for histone-modifying enzymes.

Authors:  Philip A Cole
Journal:  Nat Chem Biol       Date:  2008-10       Impact factor: 15.040

4.  Histone acetyltransferase inhibitor anacardic acid causes changes in global gene expression during in vitro Plasmodium falciparum development.

Authors:  Long Cui; Jun Miao; Tetsuya Furuya; Qi Fan; Xinyi Li; Pradipsinh K Rathod; Xin-Zhuan Su; Liwang Cui
Journal:  Eukaryot Cell       Date:  2008-05-16

Review 5.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

Review 6.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

Review 7.  Therapeutic strategies to inhibit MYC.

Authors:  Michael R McKeown; James E Bradner
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

8.  The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.

Authors:  Lan Wang; Alexander Gural; Xiao-Jian Sun; Xinyang Zhao; Fabiana Perna; Gang Huang; Megan A Hatlen; Ly Vu; Fan Liu; Haiming Xu; Takashi Asai; Hao Xu; Tony Deblasio; Silvia Menendez; Francesca Voza; Yanwen Jiang; Philip A Cole; Jinsong Zhang; Ari Melnick; Robert G Roeder; Stephen D Nimer
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

Review 9.  Ghrelin O-acyltransferase assays and inhibition.

Authors:  Martin S Taylor; Yousang Hwang; Po-Yuan Hsiao; Jef D Boeke; Philip A Cole
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

10.  Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition.

Authors:  Beverley M Dancy; Nicholas T Crump; Daniel J Peterson; Chandrani Mukherjee; Erin M Bowers; Young-Hoon Ahn; Minoru Yoshida; Jin Zhang; Louis C Mahadevan; David J Meyers; Jef D Boeke; Philip A Cole
Journal:  Chembiochem       Date:  2012-09-07       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.